Predicting the molecular mechanism of glucosamine in accelerating bone defect repair by stimulating osteogenic proteins

Gani, Maria Apriliani; Nurhan, Ahmad Dzulfikri; Budiatin, Aniek Setiya; Siswodihardjo, Siswandono; Khotib, Junaidi

doi:10.1515/jbcpp-2020-0403

Cited by 14 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone defect is a serious condition caused by pathological circumstances. 1,2 Bones can heal themselves through self-healing mechanisms. However, this mechanism is inconvenient for large gap sizes, leading to various complications.…”

Section: Introductionmentioning

confidence: 99%

Bovine hydroxyapatite-based scaffold accelerated the inflammatory phase and bone growth in rats with bone defect

Gani

Budiatin

Shinta

et al. 2023

Journal of Applied Biomaterials & Functional Materials

Self Cite

View full text Add to dashboard Cite

Hydroxyapatite (HA) is a biomaterial widely used to treat bone defect, such as due to traffic accident. The HA scaffold is obtained from synthetic HA or natural sources, such as bovine hydroxyapatite (BHA). This study aims to compare the characteristics and in vivo performance of BHA-based and HA-based scaffolds. For this purpose, the scaffold was formulated with gelatin (GEL) and characterised by SEM-EDX, FTIR and mini autograph. The defect model was carried out on the femur area of Wistar rats classified into three animal groups: defect, HA-GEL and BHA-GEL. Postoperatively (7, 14 and 28 days), the bone was radiologically evaluated, and stained with haematoxylin–eosin, anti-CD80 and anti-CD163. The BHA-GEL scaffold showed a regular surface and spherical particle shape, whereas the HA-GEL scaffold exhibited irregular surface. The BHA-GEL scaffold had higher pore size and compressive strength and lower calcium-to-phosphorus ratio than the HA-GEL scaffold. In vivo study showed that the expression of CD80 in the three experimental groups was not significantly different. However, the expression of CD163 differed significantly between the groups. The BHA-GEL group showed robust expression of CD163 on day 7, which rapidly decreased over time. It also showed increased osteoclasts, osteoblasts and osteocytes cell count that contributed to the integrity of the defect area. In conclusion, the BHA-based scaffold exhibited the desired physical and chemical characteristics that benefit in vivo performance versus the HA-based scaffold. Thus, the BHA-based scaffold may be used as a bone graft.

show abstract

Section: Introductionmentioning

confidence: 99%

Bovine hydroxyapatite-based scaffold accelerated the inflammatory phase and bone growth in rats with bone defect

Gani

Budiatin

Shinta

et al. 2023

Journal of Applied Biomaterials & Functional Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ligand structure was prepared based on Gani et al . [ 16 ] In brief, structures were designed in ChemDraw 15.0.0.106 and optimized in Chem3D 15.0.0.106.…”

Section: Methodsmentioning

confidence: 99%

“…The technique of docking used in this study was the targeted docking method. [ 16 17 ] Grid box size and centers used for each protein are listed in Table 1 . The protein binding pocket used in the present study was also validated with DoGSiteScorer.…”

Section: Methodsmentioning

confidence: 99%

Computational approach in searching for dual action multitarget inhibitors for osteosarcoma

Gani¹,

Nurhan²,

Putri³

et al. 2023

Journal of Advanced Pharmaceutical Technology &Amp; Research

View full text Add to dashboard Cite

Osteosarcoma is a common primary malignant bone tumor that typically manifests in the second decade of life. This study aimed to identify osteogenic compounds that potentially serve as multitarget inhibitors for osteosarcoma. The study was a molecular docking study of nine Food and Drug Administration-approved compounds with osteogenic properties to the key membrane proteins of osteosarcoma. The ligands used were raloxifene, simvastatin, dexamethasone, risedronate, ibandronate, zoledronic acid, ascorbic acid, alendronate, and β-glycerophosphate, whereas the target proteins used were RET, fibroblast growth factor receptor 1, KIT, PDGFRA, VEGFR1, and VEGFR2. Chem3D version 15.0.0.106 was used for ligand preparation, and AutoDockTools version 1.5.6 was used for protein preparation, whereas molecular docking was conducted using AutoDock Vina. Raloxifene, simvastatin, and dexamethasone had the lowest binding activity to the target proteins. The binding affinity of raloxifene was from −8.4 to −10.0 kcal mol−1, that of simvastatin was −8.3 to −9.2 kcal mol−1, whereas dexamethasone ranged from −6.9 to −9.1 kcal mol−1. Most types of interactions were hydrophobically followed by hydrogen bonding. The current study suggests that raloxifene, simvastatin, and dexamethasone have the potential to act as multitarget inhibitors for osteosarcoma with the ability to induce bone remodeling.

show abstract

“…The increasing cases of bone defects can cause the rising cost of health treatment and lower the quality of life. − The issues of bone defects from a traffic accident, violence, sports injury, or infectious disease have been major health problems in clinical treatment. , Regularly, bones can repair themselves for minor defects but they require external treatment to guide the repairing process of larger defects (>2 cm) . The standard treatments for overcoming the bone defects problem have been autografts (obtained from the patient’s tissue) and allografts (obtained from another person) .…”

Section: Chitosan-based Biomaterials For Bone Scaffoldmentioning

confidence: 99%

Chitosan-Based Smart Biomaterials for Biomedical Applications: Progress and Perspectives

Budiarso,

Rini,

Tsalsabila

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Over the past decade, smart and functional biomaterials have escalated as one of the most rapidly emerging fields in the life sciences because the performance of biomaterials could be improved by careful consideration of their interaction and response with the living systems. Thus, chitosan could play a crucial role in this frontier field because it possesses many beneficial properties, especially in the biomedical field such as excellent biodegradability, hemostatic properties, antibacterial activity, antioxidant properties, biocompatibility, and low toxicity. Furthermore, chitosan is a smart and versatile biopolymer due to its polycationic nature with reactive functional groups that allow the polymer to form many interesting structures or to be modified in various ways to suit the targeted applications. In this review, we provide an up-to-date development of the versatile structures of chitosan-based smart biomaterials such as nanoparticles, hydrogels, nanofibers, and films, as well as their application in the biomedical field. This review also highlights several strategies to enhance biomaterial performance for fast growing fields in biomedical applications such as drug delivery systems, bone scaffolds, wound healing, and dentistry.

show abstract

Predicting the molecular mechanism of glucosamine in accelerating bone defect repair by stimulating osteogenic proteins

Cited by 14 publications

References 23 publications

Bovine hydroxyapatite-based scaffold accelerated the inflammatory phase and bone growth in rats with bone defect

Bovine hydroxyapatite-based scaffold accelerated the inflammatory phase and bone growth in rats with bone defect

Computational approach in searching for dual action multitarget inhibitors for osteosarcoma

Chitosan-Based Smart Biomaterials for Biomedical Applications: Progress and Perspectives

Contact Info

Product

Resources

About